Edition:
United Kingdom

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.55USD
8:45pm GMT
Change (% chg)

$-0.17 (-6.25%)
Prev Close
$2.72
Open
$2.75
Day's High
$2.75
Day's Low
$2.55
Volume
202,214
Avg. Vol
420,361
52-wk High
$10.65
52-wk Low
$2.30

Latest Key Developments (Source: Significant Developments)

Sorrento Therapeutics Files For Resale Of 6.3 Mln Shares Of Co By Investors
11:23am GMT 

Dec 13 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS FILES FOR RESALE OF 6.3 MILLION SHARES OF CO BY INVESTORS - SEC FILING.  Full Article

Sorrento Acquires Sofusa Lymphatic Delivery Technology Platform
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO ACQUIRES THE SOFUSA™ LYMPHATIC DELIVERY PLATFORM FOR IMMUNE-ONCOLOGY (I-O) ANTIBODY THERAPEUTICS.SORRENTO THERAPEUTICS INC - ACQUIRED SOFUSA LYMPHATIC DELIVERY TECHNOLOGY PLATFORM FROM KIMBERLY-CLARK CORPORATION.  Full Article

Sorrento Therapeutics Enteres Into Securities Purchase Agreement
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING.SORRENTO THERAPEUTICS SAYS AGREED TO ISSUE, SELL TO PURCHASERS, IN A PRIVATE PLACEMENT, CONVERTIBLE PROMISSORY NOTES IN OF $50 MILLION.  Full Article

Sorrento Therapeutics says co entered into an at market issuance sales agreement with B. Riley FBR as sales agent
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics - ‍On Nov. 9, 2017, co entered into an at market issuance sales agreement with B. Riley FBR, Inc., as sales agent - SEC Filing​.Sorrento Therapeutics Inc - ‍ Pursuant to sales agreement, co may offer and sell through agent up to $100 million in shares of common stock​.  Full Article

Sorrento Therapeutics files for mixed shelf of upto $350 mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​.  Full Article

Hong Kong market could open cash flood gates for U.S. biotechs

June 14 When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.